Daratumumab is a humanized IgG‐kappa monoclonal antibody that targets the CD38 glycoprotein on the surface of MM cells and induces specific cell cytotoxicity through antibody‐dependent binding [27]. The gene discussed is CD38; the disease is Miyoshi myopathy.